Dual-target inhibitors of colchicine binding site for cancer treatment

Lu, Lu; Li, Keke; Pu, Jiaxin; Wang, Shaochi; Liang, Tingting; Wang, Jianhong

doi:10.1016/j.ejmech.2024.116543

European Journal of Medicinal Chemistry

2024

DOI: 10.1016/j.ejmech.2024.116543

|View full text |Cite

Dual-target inhibitors of colchicine binding site for cancer treatment

Lu Lu,

Keke Li,

Jiaxin Pu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Discovery of novel quinazoline derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potential anti-colon cancer effects

Zhu,

Zhang,

Leng

et al. 2024

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Discovery of novel quinazoline derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potential anti-colon cancer effects

Zhu,

Zhang,

Leng

et al. 2024

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site

Lai,

Wang,

et al. 2025

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Case report: Systemic sclerosis during neoadjuvant therapy for breast cancer in a 59-year-old woman

Liu,

Xiao,

Yue

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is an autoimmune connective tissue disease with skin fibrosis being the first and most common manifestation. Patients with SSc have a higher risk of developing malignant tumors than the general population. However, the sequence and underlying mechanisms linking SSc to malignancy remain controversial. This article presents the case of a 59-year-old woman who was diagnosed with SSc after developing skin fibrosis during neoadjuvant therapy for breast cancer. Despite aggressive antitumor treatments, including targeted therapy, SSc did not improve and progressed rapidly with increasing dermatofibrosis. Remarkably, the SSc entered remission following the cessation of antitumor therapy. Additionally, we reviewed the literature on SSc and malignant tumors, examined their relationship, and discussed key points regarding their identification and potential for adverse drug reactions.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Dual-target inhibitors of colchicine binding site for cancer treatment

Cited by 4 publications

References 67 publications

Discovery of novel quinazoline derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potential anti-colon cancer effects

Discovery of novel quinazoline derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potential anti-colon cancer effects

Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site

Case report: Systemic sclerosis during neoadjuvant therapy for breast cancer in a 59-year-old woman

Contact Info

Product

Resources

About